KNSA FY 2017 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$28,000

Operating Income

-$65M

Net Income

-$65M

EPS (Diluted)

$-2.00

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$50M

Stock-Based Comp.

$897,000

Balance Sheet

Total Assets

$47M

Total Liabilities

$137M

Stockholders' Equity

-$90M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$28,000	-$22,000	-27.3%
Operating Income	-$65M	-$24M	-172.5%
Net Income	-$65M	-$24M	-170.6%